drugset / Trial / NCT01082146

RI-AME Study OF [ISOTHIAZOLYL-3-14C]-LURASIDONE

NCT01082146

Phase 1 Completed 6 enrolled Sumitomo Pharma America, Inc.
NaSingle-groupOpen-label

Summary

This will be an open-label, non-randomized, absorption, metabolism, and excretion study of Lurasidone administered in a suspension at 40 mg to 6 normal healthy male subjects in a postprandial state

Timeline

Start
2008-08
Primary completion
2008-08
Completion
2008-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Lurasidone Small molecule 40 mg Oral

Indications

No indication recorded.